

EMPLICURE INTERIM REPORT Q2, 2022

- There is great interest in our unique patented bioceramic technology, which provides the opportunity to develop the next generation of nicotine pouches

Second quarter, April-June 2022

- Net sales amounted to MSEK 0.0 (0.1)
- Operating loss (EBIT) amounted to MSEK -8.7 (-6.5)
- Net loss amounted to MSEK -8.7 (-7.9)
- Net cash flow amounted to MSEK +3.8 (-6.2)
- EPS before and after dilution amounted to SEK -0.37 (-0.68)

January-June 2022

- Net sales amounted to MSEK 0.0 (0.1)
- Operating loss (EBIT) amounted to -16.0 (-7.5)
- Net loss amounted to MSEK -16.0 (-9.3)
- Net cash flow amounted to MSEK -1.7 (+3.3)
- EPS before and after dilution amounted to SEK -0.73 (-0.80)

Adviser

Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

For more information, please contact:

Torbjörn W. Larsson

CEO

Phone: +46 (0)70 747 65 99

Email: twl@emplicure.com

Erik Magnusson

CFO, Investor Relations

Phone: +46 (0)70 856 52 45

Email: erik.magnusson@emplicure.com

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on August 18, 2022 at 08:30 CET.



Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. Wholly owned subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com